Atlas Trials

A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old

Clinical trial NCT07722546 · RECRUITING

Trial details

NCT number
NCT07722546
Sponsor
Biogen
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Graves' Disease
Start date
2026-07-30
Primary completion
2028-01-31
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.